A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma

Authors: Berg W.J.¹; McCaffrey J.¹; Schwartz L.H.²; Mariani T.¹; Mazumdar M.³; Motzer R.J.¹; Motzer R.J.⁴

Source: Investigational New Drugs, Volume 16, Number 4, 1998 , pp. 337-340(4)

Publisher: Springer

Buy & download fulltext article:

Price: $47.00 plus tax (Refund Policy)

Abstract:

The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m^2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.

Keywords: advanced renal cell carcinoma; pyrazoloacridine

Language: English

Document Type: Regular paper

Affiliations: 1: Genitourinary Oncology Service, Division of Solid Tumor Oncology 2: Department of Radiology 3: Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York 4: Department of Medicine, Cornell University Medical College, New York, NY, USA

Publication date: 1998-01-01